James H McKerrow MD
Anatomic Pathology, Clinical Pathology
Professor, Pathology, UCSF School of Medicine
Join to View Full Profile
350 Parnassus AveSan Francisco, CA 94117
Phone+1 415-476-2960
Fax+1 415-502-8193
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. James McKerrow, MD is a board certified pathologist in San Francisco, California. He is currently licensed to practice medicine in California. He is a Professor at UCSF School of Medicine.
Education & Training
University of California (San Francisco)Residency, Pathology-Anatomic and Clinical, 1977 - 1978
Stony Brook Medicine/University HospitalInternship, Internal Medicine, 1976 - 1977
Stony Brook University Health Sciences Center School of MedicineClass of 1976
Certifications & Licensure
CA State Medical License 1977 - 2026
American Board of Pathology Anatomic Pathology
Publications & Presentations
PubMed
- Identification of Substituted 4-Aminocinnolines as Broad-Spectrum Antiparasitic Agents.Andrew Spaulding, Amrita Sharma, Miriam A Giardini, Benjamin Hoffman, Jean A Bernatchez
ACS Infectious Diseases. 2025-03-14 - Computational Workflow to Design Novel Vaccine Candidates and Small-Molecule Therapeutics for Schistosomiasis.Emmanuel Oluwadare Balogun, Gideon Ibrahim Joseph, Samuel Charles Olabode, Naziru Abdulkadir Dayaso, Ammar Usman Danazumi
Pathogens. 2024-09-30 - 5 citationsHuman schistosomiasis in Nigeria: present status, diagnosis, chemotherapy, and herbal medicines.Umar Saidu, Mohammed Auwal Ibrahim, Harry P de Koning, James H McKerrow, Conor R Caffrey
Parasitology Research. 2023-12-01
Press Mentions
Experimental Therapy for Parasitic Heart Disease – K777 – May Also Help Stop COVID-19April 6th, 2021- Selva Raises $3m to Develop Novel Antiviral Against Covid-19August 12th, 2020
- Broad Spectrum Antiviral Oral Therapy Demonstrates High Potency Against COVID-19 in in Vitro Triggering Investor Demand to Fund Series A Round in Selva TherapeuticsJuly 21st, 2020
- Join now to see all
